The Brain Drug Nobody’s Talking About Just Got Published in Nature
Spinogenix publishes peer-reviewed Phase 2 data for SPG601 in Fragile X Syndrome in Nature Scientific Reports.
Jeff Martin
The Government Bet $15M That This Receptor Exists
Sparian Biosciences starts Phase 1 of SBS-147, a non-opioid pain drug funded by a $15M NIH HEAL grant.
“Cue” The Music. $7.5M for Picking the Right Molecule.
Cue Biopharma earns a $7.5M preclinical milestone from Boehringer Ingelheim for its CUE-501 autoimmune program.
83% Tumor Kill Rate. One Shot. Published in Nature.
Trogenix publishes preclinical GBM gene therapy data in Nature showing 83% complete tumor eradication from a single dose.
An Oral Pill for Glioblastoma. From Oslo.
Hemispherian doses first patients in a Phase 1/2a trial of GLIX1, a first-in-class oral TET2 activator for glioblastoma.
One Patient. One B Cell. A Whole New Playbook.
Immusoft presents the world's first engineered B cell therapy patient data at an FDA workshop.
$465M Partnership. 59% Response Rate. $5B Buyout.
Gilead Sciences acquires ADC developer Tubulis for up to $5 billion, turning a 2023 partnership into a full buyout.
Edit the RNA. Keep the DNA. Fix the Disease.
AIRNA doses first patient in Phase 1 of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency.
ADCs Hit a Wall. This Company Brought a Different Weapon.
ABION shows preclinical data at AACR 2026 where its IFN-β antibody fusion ABN202 outperformed TROP2 ADCs in resistant tumors.
Two Oral Alzheimer’s Drugs. One Company. No IV Poles.
Alzheon doses first subject in Phase 1 of ALZ-507, its second oral anti-amyloid inhibitor with an APOE4-corrector twist.